{"ATVI": {"Ticker": "ATVI", "Company": "Activision Blizzard", "Sector": "Communication Services", "Updated": "2022-07-25", "Rating": [{"Date": "2022-07-25", "Rating": "Upgrade", "Organization": "MoffettNathanson", "Rating_Change": "Neutral to Buy", "Target_Change": "$95"}], "Score": 2.0, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 1, "Period": "180 days", "Letter_Rating": "A", "Analists": ["MoffettNathanson"], "Price_Target": 95.0}, "IDXX": {"Ticker": "IDXX", "Company": "Idexx Laboratories", "Sector": "Health Care", "Updated": "2022-07-25", "Rating": [{"Date": "2022-07-25", "Rating": "Downgrade", "Organization": "Stifel", "Rating_Change": "Buy to Hold", "Target_Change": "$415"}, {"Date": "2022-07-21", "Rating": "Upgrade", "Organization": "Goldman", "Rating_Change": "Neutral to Buy", "Target_Change": "$530 to $435"}, {"Date": "2022-07-12", "Rating": "Initiated", "Organization": "Piper Sandler", "Rating_Change": "Overweight", "Target_Change": "$440"}, {"Date": "2022-05-05", "Rating": "Downgrade", "Organization": "BofA Securities", "Rating_Change": "Buy to Neutral", "Target_Change": "$550 to $470"}], "Score": 0.5, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 4, "Period": "180 days", "Letter_Rating": "B", "Analists": ["Piper Sandler", "Goldman", "Stifel", "BofA Securities"], "Price_Target": 440.0}, "LRCX": {"Ticker": "LRCX", "Company": "Lam Research", "Sector": "Information Technology", "Updated": "2022-07-25", "Rating": [{"Date": "2022-07-25", "Rating": "Downgrade", "Organization": "Barclays", "Rating_Change": "Overweight to Equal Weight", "Target_Change": "$625 to $450"}, {"Date": "2022-06-15", "Rating": "Downgrade", "Organization": "B. Riley Securities", "Rating_Change": "Buy to Neutral", "Target_Change": "$625 to $525"}], "Score": -1.5, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "D", "Analists": ["Barclays", "B. Riley Securities"], "Price_Target": 487.5}, "PAYC": {"Ticker": "PAYC", "Company": "Paycom", "Sector": "Information Technology", "Updated": "2022-07-25", "Rating": [{"Date": "2022-07-25", "Rating": "Downgrade", "Organization": "DA Davidson", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2022-06-23", "Rating": "Resumed", "Organization": "KeyBanc Capital Markets", "Rating_Change": "Overweight", "Target_Change": "$400 to $340"}], "Score": 0.5, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "B", "Analists": ["KeyBanc Capital Markets", "DA Davidson"], "Price_Target": 340.0}, "REGN": {"Ticker": "REGN", "Company": "Regeneron Pharmaceuticals", "Sector": "Health Care", "Updated": "2022-07-25", "Rating": [{"Date": "2022-07-25", "Rating": "Downgrade", "Organization": "SVB Leerink", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": "$630"}, {"Date": "2022-07-13", "Rating": "Initiated", "Organization": "Cantor Fitzgerald", "Rating_Change": "Neutral", "Target_Change": "$625"}, {"Date": "2022-06-06", "Rating": "Initiated", "Organization": "Jefferies", "Rating_Change": "Underperform", "Target_Change": "$536"}, {"Date": "2022-05-23", "Rating": "Initiated", "Organization": "SVB Leerink", "Rating_Change": "Outperform", "Target_Change": "$738"}], "Score": -0.25, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 4, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Jefferies", "Cantor Fitzgerald", "SVB Leerink"], "Price_Target": 632.25}, "SIVB": {"Ticker": "SIVB", "Company": "SVB Financial", "Sector": "Financials", "Updated": "2022-07-25", "Rating": [{"Date": "2022-07-25", "Rating": "Upgrade", "Organization": "Evercore ISI", "Rating_Change": "In-line to Outperform", "Target_Change": "$430"}, {"Date": "2022-07-22", "Rating": "Downgrade", "Organization": "Keefe Bruyette", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": "$600 to $450"}, {"Date": "2022-06-30", "Rating": "Downgrade", "Organization": "Wedbush", "Rating_Change": "Outperform to Neutral", "Target_Change": ""}, {"Date": "2022-05-04", "Rating": "Upgrade", "Organization": "Argus", "Rating_Change": "Hold to Buy", "Target_Change": ""}, {"Date": "2022-05-03", "Rating": "Upgrade", "Organization": "Oppenheimer", "Rating_Change": "Perform to Outperform", "Target_Change": "$702"}], "Score": -0.2, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 5, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Oppenheimer", "Keefe Bruyette", "Argus", "Evercore ISI", "Wedbush"], "Price_Target": 527.33}, "TRV": {"Ticker": "TRV", "Company": "The Travelers Companies", "Sector": "Financials", "Updated": "2022-07-25", "Rating": [{"Date": "2022-07-25", "Rating": "Upgrade", "Organization": "Raymond James", "Rating_Change": "Mkt Perform to Strong Buy", "Target_Change": "$185"}, {"Date": "2022-06-23", "Rating": "Downgrade", "Organization": "Wolfe Research", "Rating_Change": "Outperform to Peer Perform", "Target_Change": "$185 to $156"}, {"Date": "2022-06-03", "Rating": "Downgrade", "Organization": "Goldman", "Rating_Change": "Neutral to Sell", "Target_Change": "$190 to $170"}, {"Date": "2022-05-24", "Rating": "Initiated", "Organization": "Citigroup", "Rating_Change": "Neutral", "Target_Change": "$179"}], "Score": -0.25, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 4, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Goldman", "Wolfe Research", "Raymond James", "Citigroup"], "Price_Target": 172.5}, "UAL": {"Ticker": "UAL", "Company": "United Airlines", "Sector": "Industrials", "Updated": "2022-07-25", "Rating": [{"Date": "2022-07-25", "Rating": "Downgrade", "Organization": "Susquehanna", "Rating_Change": "Positive to Neutral", "Target_Change": "$35"}, {"Date": "2022-07-07", "Rating": "Downgrade", "Organization": "Exane BNP Paribas", "Rating_Change": "Neutral to Underperform", "Target_Change": "$38 to $33"}, {"Date": "2022-07-07", "Rating": "Downgrade", "Organization": "Argus", "Rating_Change": "Buy to Hold", "Target_Change": ""}, {"Date": "2022-05-06", "Rating": "Upgrade", "Organization": "Wolfe Research", "Rating_Change": "Underperform to Peer Perform", "Target_Change": ""}], "Score": -1.0, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 4, "Period": "180 days", "Letter_Rating": "D", "Analists": ["Exane BNP Paribas", "Argus", "Wolfe Research", "Susquehanna"], "Price_Target": 34.0}}